Systemic Activation of the Kynurenine Pathway in Graves Disease With and Without Ophthalmopathy
An erratum to this article was published (J Clin Endocrinol Metab, 17 May 2023 ↗)
Authors' conclusion
This study supports activation of IFN-γ inflammation and Th1 cellular immunity in GD, but also a contribution of acute-phase reactants. Our finding of no difference in systemic activation of the kynurenine pathway in GD patients with and without TED implies that the local Th1 immune response in the orbit is not reflected systemically.
Study context
- Population
- Patients with graves disease (GD), with and without thyroid eye disease (TED), and matched healthy controls; serum analysis of 34 biomarkers (kynurenine pathway metabolites and indices, microbiota-derived metabolites, B-vitamers, serum proteins of inflammation and kidney function)
- Participants
- 100 vs 100
- Comparison
- GD patients vs matched healthy controls; GD with vs without TED
- GDn = 100
- Healthy controlsn = 100reference
- Outcome
- Serum biomarker levels, GD vs healthy controls
Methodological detailsmatched healthy controls, mass spectrometry
- Matched healthy controls
- Mass spectrometry
Main finding
As reported in the abstract
- Significantly elevated biomarkers in GD vs healthy controls (ω2 > 0.06; P < .01)
- 7
Observational data: associations, not effects.
Further findings
- No differences in biomarker levels between GD patients with and without TED
Original publication
Systemic Activation of the Kynurenine Pathway in Graves Disease With and Without Ophthalmopathy. J Clin Endocrinol Metab. Published 6 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →